Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Nadofaragene firadenovec / nadofaragene firadenovec-vncg & Bladder cancer, on December 16, 2022, the FDA granted approval for nadofaragene firadenovec-vncg. This approval is for its use as an intravesical gene therapy specifically designed for adult patients who have high-risk, BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC). This includes cases with carcinoma in situ, whether or not papillary tumors are present (1, 2, 3, 4).
The clinical phase III trial, identified as NCT02773849, demonstrated that intravesical nadof…